🫧 Edgar looked up Core Scientific, Inc./tx ($CORZ). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-10. 26 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-03-13. Non-reliance (8-K Item 4.02) filed 2026-03-02.
🔖 Exposure: revenue $319.0M (FY2025). Experience: revenue down 37.5% on the year, down 12.5% a year over 4 years; operating margin -77.0%, down from -27.8%. Soundness: equity -41.0% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $157.5M and $314.2M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $132.2M to $376.9M. A statistical range, not company guidance. Against peers (36 filers, $50M+ revenue, finance services): operating margin -77.0% against a -6.4% median; growth -37.5% against 16.8%.
| Fiscal year end | 2025-12-31 |
| Revenue | $319M |
| Revenue, on the year | −37.5% |
| Revenue, a year over the record | −12.5% |
| Operating margin | −77.0% |
| Operating margin, prior year | −27.8% |
| Net margin | −90.5% |
| Research and development | not filed separately |
| Free cash flow | −$451M |
| Cash | $311M |
| Total debt | — |
| Equity of assets | −41.0% |
| Return on equity | — |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.88 |
| Book value per share | $-3.03 |
| Revenue per share | $1.00 |
| Shares outstanding | 318,068,000 |
| Audited years read | 5 |
Peers: the median of 36 filers with $50M+ revenue in finance services.
Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt.
Tied up at the dock.
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Both views must agree for a label · market view (price) not sourced; add a price at /boards/ask.json?q=TICKER&price=… · a description, not advice.
| Cash conversion (operating cash ÷ revenue) | 87.2% |
| Growth speed (3 years, per year) | -20.7% |
| Revenue swing (std-dev of yearly growth) | 28.0% |
| Speed and steadiness | Slow and jumpy |
| Common dividend | none |
| Equity of assets | -41.0% |
Core Scientific, Inc./tx is growing slower than its size class, with revenue that swings more. SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company
Or tap watch on any row above. One note the day they file, from Edgar, each with a one-click stop link. Handled to EU GDPR and Japan APPI standards.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time (757) 390-0424Nine boards reading every SEC filing the day it lands, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.